O'Hagan Daniel, Shandilya Siddhartha, Hopkins Lincoln J, Hahn Patricia A, Fuchs Sebastian P, Martinez-Navio José M, Alpert Michael D, Gardner Mathew R, Desrosiers Ronald C, Gao Guangping, Lifson Jeffrey D, Farzan Michael, Ardeshir Amir, Martins Mauricio A
Department of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, Jupiter, FL 33458, USA.
California National Primate Research Center, University of California, Davis, Davis, CA 95616, USA.
Mol Ther. 2025 Feb 5;33(2):560-579. doi: 10.1016/j.ymthe.2024.12.015. Epub 2024 Dec 12.
eCD4-immunoglobulin (Ig) is an HIV entry inhibitor that mimics the engagement of both CD4 and CCR5 with the HIV envelope (Env) protein, a property that imbues it with remarkable potency and breadth. However, env is exceptionally genetically malleable and can evolve to escape a wide variety of entry inhibitors. Here we document the evolution of partial eCD4-Ig resistance in SHIV-AD8-infected rhesus macaques (RMs) treated with adeno-associated virus vectors encoding eCD4-Ig. In one RM, setpoint viremia plateaued at 1,000 vRNA copies/mL, despite concomitant serum concentrations of eCD4-Ig in the 60-110 μg/mL range, implying that the virus had gained partial eCD4-Ig resistance. Env mutations occurring prominently in this animal were cloned and further characterized. Three of these mutations (R315G, A436T, and G471E) were sufficient to confer substantial resistance to eCD4-Ig-mediated neutralization onto the parental Env, accompanied by a marked loss of viral fitness. This resistance was not driven by decreased CD4 affinity, subverted sulfopeptide mimicry, changes to co-receptor tropism, or by a gain of CD4 independence. Rather, our data argue that the Env evolving in this animal attained eCD4-Ig resistance by decreasing triggerability, stabilizing the triggered state, and changing the nature of its relationship to the host CD4.
eCD4免疫球蛋白(Ig)是一种HIV进入抑制剂,它模拟CD4和CCR5与HIV包膜(Env)蛋白的结合,这一特性使其具有显著的效力和广度。然而,Env在基因上具有极强的可塑性,能够进化以逃避多种进入抑制剂。在此,我们记录了用编码eCD4-Ig的腺相关病毒载体治疗的感染SHIV-AD8的恒河猴(RM)中部分eCD4-Ig耐药性的演变。在一只RM中,尽管血清中eCD4-Ig浓度在60-110μg/mL范围内,但设定点病毒血症稳定在1000个病毒RNA拷贝/毫升,这意味着病毒已获得部分eCD4-Ig耐药性。对在这只动物中显著出现的Env突变进行了克隆和进一步表征。其中三个突变(R315G、A436T和G471E)足以赋予亲本Env对eCD4-Ig介导的中和作用的实质性抗性,同时伴随着病毒适应性的显著丧失。这种抗性不是由CD4亲和力降低、被破坏的硫肽模拟、共受体嗜性的改变或CD4独立性的获得所驱动的。相反,我们的数据表明,在这只动物中进化的Env通过降低可触发能力、稳定触发状态以及改变其与宿主CD4关系的性质而获得了eCD4-Ig抗性。